Sequence Note

Evidence of Recombination between 3' and 5' LTRs in Macaques Inoculated with SIV DNA

STEPHEN J. KENT,1,2 C. JANE DALE,1,2 SCOTT PREISS,1,2 and DAMIAN F.J. PURCELL1,2

ABSTRACT

Proviral SIV DNA inoculation of macaques is an efficient method to initiate wild-type and attenuated SIV infections. However, we found that macaques inoculated with SIV DNA engineered to contain a single 105-bp deletion in the 3' nef/LTR overlap region had SIV sequences subsequently isolated that had partially or fully repaired the deletion with wild-type sequence. Animals inoculated with SIV DNA containing identical deletions in both the 5' and 3' LTRs did not repair the deletion. Recombination events occurred early, most likely by homologous recombination with sequences from the wild-type 5' LTR. This sequence analysis is the first demonstration of homologous recombination in vivo following administration of a single SIV strain.

INTRODUCTION

We have studied the initiation of wild-type and attenuated simian immunodeficiency virus (SIV) infections in macaques by administration of proviral SIV DNA.1 Wild-type and attenuated SIV infections can be initiated utilizing as little as 15 μg of SIV DNA, providing a feasible means to manufacture and deliver live attenuated HIV vaccines should they ultimately prove sufficiently safe and effective. Humans with attenuated HIV-1 infections, including the Sydney Blood Bank Cohort, have focused attention on deletions that overlap the nef and 3' long terminal repeat (LTR) genes.2 Macaque studies have suggested some level of ongoing SIV replication is required in order to generate protective immunity.3 In the initial considerations on the design of plasmids for the initiation of attenuated SIV infections, we hypothesized that the efficient initiation of an SIV infection might require a strong first round of viral replication from an intact 5' LTR. We previously demonstrated a reduction in gene expression in macaques and in humans following introduction of reporter gene expression from deleted LTRs.4 Since subsequent rounds of replication would duplicate a deleted 3' LTR into the 5' LTR (Fig. 2), we hypothesized that an intact 5' LTR in the inoculated plasmid would facilitate the initial round of transcription but that subsequent rounds would contain only the attenuating deletion in both LTRs.

To assess the sequence stability of attenuated SIV plasmids inoculated into pigtailed macaques, a series of full-length SIVmac239 proviral plasmids were engineered. The plasmids were either wild-type sequence (pSIVmac239), contained a single in frame 105-bp deletion in the 3' nef/LTR overlap region (pSIVsbbcdΔ3), or contained identical deletions in the 3' nef/LTR overlap region and 5' LTR (pSIVsbbΔ3Δ5, Figs. 1 and 2).5 The plasmids were inoculated into macaques either intramuscularly or intradermally via gene gun in studies approved by the relevant institutional animal ethics committee. To assess the stability of the introduced deletions, DNA was extracted from serial peripheral blood mononuclear cell (PBMC) samples of all SIV DNA-inoculated animals and subjected to nested PCR across the nef/LTR overlap region as described.5 Representative clones were made into the pCRII-topo vector (Invitrogen, San Diego, CA) and inserts sequenced using the dideoxy method on an automated sequencer (Applied Biosystems, Foster City, CA).

All four animals inoculated with wild-type pSIVmac239 progressed to AIDS within 1 year and had SIV nef/LTR DNA of wild-type size amplified from PBMC by nested PCR at every time point examined following DNA inoculation.1 Sequencing

1Department of Microbiology and Immunology, University of Melbourne, Parkville, Vic, 3010, Australia.
2Macfarlane Burnet Centre for Medical Research, Yarra Bend Rd, Fairfield, Vic, 3078, Australia.
FIG. 1. Predicted amino acid sequences from the SIV nef/LTR region. The sequence was derived from cloned PCR products of macaque PBMC DNA following SIV DNA inoculation. The top line shows the sequence from the SIVmac239 plasmid as the reference, the second line the pSIVmacΔ3 plasmid, and the bottom line the SIVmac251 challenge strain. Identical sequence is annotated with a period (.), sequence deletions with a dash (-), and a stop codon with an asterisk (*). Clones were grouped according to the size of the PCR product, and the week (wk) of isolation after inoculation, or week postchallenge (wk p.c.). The frequency of clones is shown in parentheses. The shaded sequence illustrates clones from animals inoculated with pSIVmacΔ3 DNA that repaired the nef/LTR deletion. The SIVmac251 sequence at amino acid 222 within the nef/LTR deletion is denoted (○) to differentiate the synonymous variation between SIVmac239 (CTG) and SIVmac251 (CTA) at this position.

of the inoculated plasmid and a PBMC from one of the pSIVmac239-inoculated animals, M12 at 31 weeks postinoculation, demonstrated a wild-type sequence across the nef/LTR region (Fig. 1). The two animals inoculated with pSIVmacΔ3Δ5 containing 3' and 5' deletions, M17 and M18, did not progress to AIDS. PBMC from the pSIVmacΔ3Δ5-inoculated animals had only deleted-size nef/LTR amplified from PBMC by nested PCR and sequencing demonstrated the deletion was stable in these two animals (Fig. 1).

In contrast, of the two animals inoculated with pSIVmacΔ3, one animal, M16, progressed to AIDS after 60 weeks following inoculation. PBMC DNA from animal M16 amplified wild-type size SIVmacΔ3Δ5 by nested PCR from week 3 following SIV inoculation and thereafter. Sequencing of the nef/LTR PCR product from serial M16 PBMC samples showed that rare clones with an exact rebuilding of the entire 105-bp nef/LTR deletion to wild-type SIVmac239 sequence appeared by week 3, both at the nucleotide level (not shown) and predicted amino acid sequence (Fig. 1). The wild-type clones gradually became more predominant at weeks 5 and 12 following inoculation and, effectively competing out the attenuated sequence, became the sole isolates by week 31 following inoculation, coincident with a decline in CD4+ T cells.

Additionally, animal M14, also inoculated with pSIVmacΔ3, had rare (3 of 24) clones isolated 5 weeks following inoculation in which the 105-bp nef/LTR deletion had been partially rebuilt with a 63-bp insertion exactly homologous with the wild-type sequence (Fig. 1). At 46 weeks after DNA inoculation, 3 of 10 clones showed that the original 105-bp deletion had been completely and precisely rebuilt with the wild-type sequence, although these species never became the predominant species and the animal did not experience a decline in CD4+ T cells. This animal demonstrated a high level of T cell immunity to SIV proteins by interferon (IFN)-γ ELISPOT and thus could presumably protect it-
self from this "autologous" challenge with the recombinant wild-type SIVmac239 at this later time following inoculation. To assess the potential for attenuated SIV infections to protect from a virulent challenge, the pSIVsbcB-inoculated animals were challenged intrarectally with SIVmac239. Animals M14 and M17 were protected from challenge but M18 was not protected and experienced a decline in CD4+ T cells. Sequencing of PCR clones from M18 PBMC postchallenge demonstrated an SIVmac239 sequence within the nef/LTR deletion was present following challenge in all 10 clones examined (Fig. 1). Sequences of PCR clones from M18 in regions flanking the nef/LTR deletion showed sequences of both SIVmac251 and SIVmac239, suggesting evidence of multiple recombination events between SIVmac239 and SIVmac251 (Fig. 1).

The rapid and accurate repair of the 3' nef/LTR deletions in pSIVsbcBΔ3-inoculated macaques M14 and M16 is consistent with homologous recombination with wild-type sequences derived from the 5' LTR (which had not been mutated in an attempt to efficiently initiate transcription). This supposition is supported by the fact that infection of macaques with proviral DNA in which the nef/LTR deletions had been engineered into both 3' and 5' LTR regions did not generate any wild-type virus sequence. In vitro transfection studies with deleted HIV-1 DNA plasmids have demonstrated that homologous recombinations frequently occur, presumably by copackaging of heterologous RNA. Homologous recombination events between attenuated vaccine strains and challenge strains of SIV have occurred when two SIV strains have been inoculated concurrently, or between attenuated vaccine strains and challenge strains of SIV, as was observed in animal M18 in this study (Fig. 1). However, this is the first demonstration of homologous recombination in vivo following administration of a single SIV strain. The mechanism driving these recombination events is unclear but possibilities include (1) recombination with a copackaged rare RNA transcript that reads through the deleted 3' LTR and terminates at the poly(A) signal site in the R of the wild-type 5' LTR in the plasmid, thereby including a wild-type U3 (Fig. 2A), (2) recombination with copackaged transcripts initiating from the 3' LTR and reading through the 5' U3 to the poly(A) signal sequence in the 3' LTR (Fig. 2B), or (3) recombination between the wild-type 5' LTR of plasmid DNA and viral DNA or RNA forms.

The principal implication of this finding is that if the desired attenuation of these lentiviruses depends wholly or in part from mutations within the LTR (either of the LTR region itself or of the nef gene overlapping the LTR), such mutations will have to be engineered into both proviral LTRs to prevent rapid recombination to wild-type virus during in vivo replication. Since wild-type 5' LTR promoter activity is not required for efficient initiation of infection in vivo, and it poses a major safety hazard, it argues that any mutations in the LTR region used in live attenuated vaccines should be made in both proviral LTRs.
ACKNOWLEDGMENTS

We acknowledge D. Campagna and J. Mills for providing excellent assistance and advice. This study was supported by the International AIDS Vaccine Initiative and Commonwealth AIDS Research Grants of Australia 956043 (S.K.) and 111700 (D.P.).

REFERENCES


Address reprint requests to:
Stephen J. Kent
Department of Microbiology and Immunology
University of Melbourne
Parkville, Vic, 3010, Australia

E-mail: skent@unimelb.edu.au